SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs rally is being tied to anticipation of Patrick Soon-Shiongs Piper Sandler fireside chat and possible trial updates, with bladder-cancer milestones and broader immunotherapy programs adding to the discussion. Traders are divided over whether the move reflects buying ahead of catalysts or short covering; partnership rumors remain unconfirmed.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention after breaking to new highs amid strong momentum in software stocks and interest in AI-related observability. Bulls see continued sector strength, while bears point to the companys rich valuation and warn of a possible reversal.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs planned acquisition of low-band spectrum for Starlink Mobile has fueled concerns that it could eventually compete with T-Mobile and other major wireless carriers, contributing to a sharp selloff. Traders are divided between seeing a lasting competitive threat and calling the reaction overblown given the infrastructure and time needed to build a rival network.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing sovereign AI demand and customized software opportunities, has helped fuel attention as Palantir shares reach fresh highs. Bulls are celebrating the momentum and speculating about a short squeeze, while skeptics argue the valuation is stretched.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas non-binding proposal to acquire its first U.S. data center and expand its AI infrastructure footprint is driving discussion. Some traders see U.S. expansion as a positive step, while many are concerned about how the capital-intensive plan will be financed and want proof of execution on existing projects first.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHounds prolonged slide to 52-week lows is drawing attention despite traders citing its Intel partnership, Kia deployment and new restaurant deals. The community is split between hopes that heavy short interest and upcoming earnings could spark a rebound, and concerns about dilution, ongoing losses and management execution.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs planned acquisition of low-band spectrum to expand Starlink Mobile has fueled a sharp selloff in Verizon shares amid concerns about future wireless competition. Traders are divided between seeing a serious long-term threat and calling the reaction an overreaction given the years and infrastructure needed to build a competing network; some are buying the dip for Verizons dividend.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention for Starknets privacy and Bitcoin DeFi push, especially strkBTC and STRK20, alongside its post-quantum security narrative. Traders are cheering the recent price-and-volume momentum, while others remain cautious about token unlocks and whether the rally can hold.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellias FDA acceptance of the lonvo-z application for priority review is the main catalyst, bringing its potential one-time hereditary angioedema treatment closer to a regulatory decision. Traders are bullish on the clinical progress and commercialization prospects, while others question adoption, financing needs, and the stocks weak, volatile response; some also point to continued ARK buying.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

AGNCs steep selloff has traders focused on rising Treasury yields and mortgage-backed securities repricing, which can pressure the mortgage REITs book value. Income-focused holders are buying the dip for its monthly dividend, while skeptics warn the decline could continue and question whether the payout is sustainable.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win 

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding

Equity

Lilly’s Foundayo 17.2 mg achieved a 1.5% greater weight loss and a 0.3% greater reduction in A1C than oral semaglutide 25 mg after 52 weeks.


VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff 

Viking Therapeutics priced an upsized financing deal at a 16% discount from the stock’s closing price on Wednesday.


VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance 

Viking Therapeutics’ experimental obesity drug showed it could preserve most patients’ prior weight loss with less frequent dosing.


Novo Nordisk Targets Over Five New Blockbusters By 2030, But NVO Stock Slides On Growth Concerns 

Novo Nordisk’s long-term growth targets failed to ease investor concerns over Eli Lilly’s obesity-drug lead, CagriSema’s comparative performance and upcoming semaglutide patent expirations.


Novo Nordisk Taps Anthropic’s Claude Science To Speed Up Drug Discovery — Here’s Everything Investors Need To Know

Novo will use Anthropic’s Claude Science in R&D to tackle scientific and drug discovery challenges, aiming to develop new medicines faster.


NVO To Present Fresh Data From Blockbuster Wegovy Pill At European Conference As Rival Eli Lilly Readies Its Own Obesity Updates

Novo said it will present 44 abstracts at the European Association for the Study of Diabetes symposium later this month.


NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity 

Morgan Stanley downgraded Novo to ‘Underweight’ from ‘Equal Weight’ while keeping its $40 price target, a 7% downside from current levels.


Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’

In an interview with CNBC, CEO David Ricks said the company’s long-term strategy includes making its obesity franchise more durable and investing in technologies to transform the treatment of other diseases.

Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus 

Mounjaro produced an 8% lower rate of cardiovascular death, heart attack or stroke than Lilly’s diabetes drug Trulicity.

Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

OZEM Roundhill GLP-1 & Weight Loss ETF

Fundamentals

Latest OZEM News